Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2368685
Max Phase: Preclinical
Molecular Formula: C32H44N2O20P2
Molecular Weight: 838.65
Molecule Type: Small molecule
Associated Items:
ID: ALA2368685
Max Phase: Preclinical
Molecular Formula: C32H44N2O20P2
Molecular Weight: 838.65
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: O=c1ccn([C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)O[C@H]3O[C@@H](COCCOCCOCCOCc4ccc5ccccc5c4)[C@H](O)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c(=O)[nH]1
Standard InChI: InChI=1S/C32H44N2O20P2/c35-24-7-8-34(32(41)33-24)30-28(39)26(37)23(51-30)18-50-55(42,43)54-56(44,45)53-31-29(40)27(38)25(36)22(52-31)17-49-14-12-47-10-9-46-11-13-48-16-19-5-6-20-3-1-2-4-21(20)15-19/h1-8,15,22-23,25-31,36-40H,9-14,16-18H2,(H,42,43)(H,44,45)(H,33,35,41)/t22-,23+,25-,26+,27-,28+,29-,30+,31+/m0/s1
Standard InChI Key: DLIIRGQJAJBNLE-OXAWKINHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 838.65 | Molecular Weight (Monoisotopic): 838.1963 | AlogP: -1.37 | #Rotatable Bonds: 21 |
Polar Surface Area: 313.68 | Molecular Species: ACID | HBA: 19 | HBD: 8 |
#RO5 Violations: 3 | HBA (Lipinski): 22 | HBD (Lipinski): 8 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 1.73 | CX Basic pKa: | CX LogP: -1.78 | CX LogD: -6.53 |
Aromatic Rings: 3 | Heavy Atoms: 56 | QED Weighted: 0.05 | Np Likeness Score: 0.67 |
1. Takaya K, Nagahori N, Kurogochi M, Furuike T, Miura N, Monde K, Lee YC, Nishimura S.. (2005) Rational design, synthesis, and characterization of novel inhibitors for human beta1,4-galactosyltransferase., 48 (19): [PMID:16162007] [10.1021/jm0504297] |
Source(1):